Can-Fite BioPharma Ltd. (CANF)

NYSEAMERICAN: CANF · Delayed Price · USD
0.901
-0.013 (-1.43%)
At close: May 18, 2022 4:00 PM
0.924
0.023 (2.563%)
Pre-market:May 19, 2022 8:11 AM EDT
Market Cap25.12M
Revenue (ttm)853,000
Net Income (ttm)-12.62M
Shares Out27.88M
EPS (ttm)-0.81
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume82,438
Open0.903
Previous Close0.914
Day's Range0.859 - 0.930
52-Week Range0.780 - 2.620
Beta1.66
Analystsn/a
Price Targetn/a
Earnings DateMay 26, 2022

About CANF

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of ...

IndustryBiotechnology
Founded1994
CEOPnina Fishman
Employees8
Stock ExchangeNYSEAMERICAN
Ticker SymbolCANF
Full Company Profile

Financial Performance

In 2021, CANF's revenue was 853,000, an increase of 11.80% compared to the previous year's 763,000. Losses were -12.62 million, -12.66% less than in 2020.

Financial numbers in millions ILSFinancial Statements

News

Can-Fite Granted Key NASH Patent in Israel

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammat...

3 days ago - Business Wire

Can-Fite's CEO to Present Namodenoson's Efficacy in Liver Cancer as Expert Speaker at the Adenosine Pathway Targeted ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammat...

2 weeks ago - Business Wire

Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model: Potenti...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite is Developing a Topical Piclidenoson Psoriasis Treatment that Shows Efficacy in a Preclinical Model

1 month ago - Business Wire

Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022

1 month ago - Business Wire

Can-Fite Reports 2021 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Reports 2021 Financial Results & Provides Clinical Update

1 month ago - Business Wire

Can-Fite: Namodenoson's Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite: Namodenoson's Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office

2 months ago - Business Wire

Can-Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Co...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can Fite's Findings in the Treatment of Liver Diseases with Cannabinoids to be Presented at CannX Medical Cannabis Conference in Tel Aviv

2 months ago - Business Wire

Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study

Citing unanticipated delay in the collection of study data, Can-Fite BioPharma Ltd (NYSE: CANF) said that the topline data from its Phase 3 Comfort study of Piclidenoson in severe plaque psoriasis would...

2 months ago - Benzinga

Can-Fite's Phase III Psoriasis Study Data Expected Q2 2022

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Phase III Psoriasis Study Data Expected Q2 2022

2 months ago - Business Wire

Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson

3 months ago - Business Wire

Is CanFite Biopharma Ltd (CANF) Outperforming Other Medical Stocks This Year?

Here is how CanFite Biopharma Ltd (CANF) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.

4 months ago - Zacks Investment Research

Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

4 months ago - Business Wire

Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address infl...

4 months ago - Business Wire

Can-Fite Issues Letter to Shareholders

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Issues Letter to Shareholders

4 months ago - Business Wire

Can-Fite (CANF) Files Patent Applications for Namodenoson

Can-Fite (CANF) files patent applications in several countries for treating all advanced solid tumors. The filing comes after Can-Fite's drug cleared all tumor lesions in advanced liver cancer.

4 months ago - Zacks Investment Research

CANF Stock: The Cancer-Fighting News Sending Can-Fite Higher Today

Can-Fite BioPharma is rising on Wednesday following positive Phase 2 data on its liver cancer treatment. Can it help turn CANF stock around?

4 months ago - InvestorPlace

Hot Penny Stocks To Watch Before Today's Opening Bell

These penny stocks are on the move, early and here's why. The post Hot Penny Stocks To Watch Before Today's Opening Bell appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks....

Other symbols:AVCTNRXPYGMZ
4 months ago - PennyStocks

Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applicatio...

PETACH TIKVA, Israel--(BUSINESS WIRE)---- $CANF--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...

4 months ago - Business Wire

Can-Fite Announces Exercise of Warrants for Cash Proceeds of $10 Million

PETACH TIKVA, Israel, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that a...

4 months ago - GlobeNewsWire

Can-Fite Shares Rally As Namodenoson Clears All Cancer Lesions In Liver Cancer Patient

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last liver cancer patient treated under an Open-Label Extension program of its concluded Phase 2 study of Namodenoson experienced a Complete Respon...

4 months ago - Benzinga

CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite BioPharma Shares Higher Today

Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer. The post CANF Stock Alert: The Liver Cancer News Catapulting Can-Fite Bi...

4 months ago - InvestorPlace

Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phas...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Liver Cancer Patient Treated with Can-Fite's Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study

4 months ago - Business Wire

5 Penny Stocks To Buy For Under $5 This Week

5 penny stocks to buy for under $5 right now. Are they worth the risk?

Other symbols:DGLYMREOOPK
4 months ago - PennyStocks

Can-Fite Expects Data Readout From Late-Stage Psoriasis Study With Piclidenoson In Q1 2022

Can-Fite BioPharma Ltd (NYSE: CANF) announced that the last of approximately 400 psoriasis patients enrolled in its Phase 3 Comfort study is scheduled to complete a 16-week cycle of treatment with Picli...

5 months ago - Benzinga

Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected ...

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022

5 months ago - Business Wire